Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ASCBQOTCMKTS:EROXOTCMKTS:ETFMOTCMKTS:LPHM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASCBQAscendia Brands$0.00$0.00▼$0.00N/AN/AN/AN/AEROXHuman Pheromone Sciences$0.00$0.00$0.00▼$0.13N/A3.313,574 shsN/AETFMFOMO$0.00$0.00$0.00▼$0.03$13.98M7.78203.35 million shsN/ALPHMLee Pharmaceuticals$0.00$0.01▼$0.40$3.48M669.9154,707 shs10.30 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASCBQAscendia Brands0.00%0.00%0.00%0.00%0.00%EROXHuman Pheromone Sciences0.00%0.00%0.00%0.00%0.00%ETFMFOMO0.00%0.00%+25.00%+1,566.67%-44.44%LPHMLee Pharmaceuticals0.00%0.00%0.00%0.00%-96.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASCBQAscendia BrandsN/AN/AN/AN/AN/AN/AN/AN/AEROXHuman Pheromone SciencesN/AN/AN/AN/AN/AN/AN/AN/AETFMFOMON/AN/AN/AN/AN/AN/AN/AN/ALPHMLee PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASCBQAscendia Brands 0.00N/AN/AN/AEROXHuman Pheromone Sciences 0.00N/AN/AN/AETFMFOMO 0.00N/AN/AN/ALPHMLee Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASCBQAscendia BrandsN/AN/AN/AN/AN/AN/AEROXHuman Pheromone SciencesN/AN/AN/AN/AN/AN/AETFMFOMON/AN/AN/AN/AN/AN/ALPHMLee PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASCBQAscendia BrandsN/AN/A0.00N/AN/AN/AN/AN/AN/AEROXHuman Pheromone SciencesN/AN/A0.00∞N/AN/AN/AN/AN/AETFMFOMO-$70KN/A0.00∞N/AN/A-6.23%-148.02%N/ALPHMLee PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASCBQAscendia BrandsN/AN/AN/AN/AN/AEROXHuman Pheromone SciencesN/AN/AN/AN/AN/AETFMFOMON/AN/AN/AN/AN/ALPHMLee PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASCBQAscendia BrandsN/AEROXHuman Pheromone SciencesN/AETFMFOMON/ALPHMLee PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipASCBQAscendia Brands49.76%EROXHuman Pheromone Sciences20.70%ETFMFOMO8.70%LPHMLee Pharmaceuticals55.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASCBQAscendia Brands324N/AN/ANot OptionableEROXHuman Pheromone Sciences3N/AN/ANot OptionableETFMFOMON/A5.59 billionN/ANot OptionableLPHMLee Pharmaceuticals135.16 million15.82 millionNot OptionableETFM, LPHM, ASCBQ, and EROX HeadlinesRecent News About These CompaniesGan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific SessionsJune 21, 2025 | prnewswire.comGan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or ObesityMarch 10, 2025 | prnewswire.comGan & Lee Pharmaceuticals divulges new antibody-drug conjugatesDecember 25, 2024 | bioworld.comBGan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two WeeksNovember 12, 2024 | prnewswire.comObesityWeek®? 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese AdultsNovember 11, 2024 | medindia.netMLongboard Pharmaceuticals (LBPH) Receives a Hold from Truist FinancialNovember 11, 2024 | markets.businessinsider.comObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese AdultsNovember 11, 2024 | prnewswire.comGan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical StudiesOctober 15, 2024 | prnewswire.comAssessing Longboard Pharmaceuticals’ Acquisition: Undervalued Potential Amidst Industry InterestOctober 14, 2024 | markets.businessinsider.comFTC Files Suit Against the Three Largest Pharmacy Benefit ManagersOctober 10, 2024 | jdsupra.comMat2A inhibitors reported in Gan & Lee Pharmaceuticals patentSeptember 27, 2024 | bioworld.comBGan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)September 14, 2024 | prnewswire.comAustin Lee ResourcingAugust 21, 2024 | pmlive.comPLee Health Embraces AI to Support Patient Care, Improve Health Outcomes, and Increase EfficiencyAugust 10, 2024 | smdailyjournal.comSFranklin Regional graduate Spencer Lee soars to semi-finals in Paris Olympics 57kg FreeStyleAugust 9, 2024 | msn.comGymnastics-Lee credits doctors and team for lifting her to Paris Olympic gloryAugust 6, 2024 | reuters.comGymnastics-Lee overcomes illness, criticism to return to Olympic podiumAugust 1, 2024 | reuters.comGan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical TrialJuly 22, 2024 | prnewswire.comGan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific SessionsJune 22, 2024 | prnewswire.comGan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific SessionsJune 17, 2024 | prnewswire.comETFM, LPHM, ASCBQ, and EROX Company DescriptionsAscendia Brands OTCMKTS:ASCBQAscendia Brands, Inc. manufactures, markets, and distributes health and beauty care products in Canada and the United States. The company offers bath, baby, oral, skin, and hair care products. Its products include bath products, baby toiletries, deodorant and antiperspirant products, home permanent treatments, mouthwash products, portable breath sprays and drops, and manual toothbrushes. The company's brand portfolio comprises Calgon, the Healing garden, Lander, and Lander essentials. It sells its products through mass merchandisers, drug stores, supermarkets, and dollar store outlets. Ascendia Brands, Inc. was formerly known as Cenuco, Inc. and changed its name to Ascendia Brands, Inc. in May 2005. The company was founded in 1920 and is based in Hamilton, New Jersey. Ascendia Brands, Inc. is in reorganization.Human Pheromone Sciences OTCMKTS:EROX$0.0004 0.00 (0.00%) As of 09/26/2022Human Pheromone Sciences, Inc. engages in the research, development, manufacture, and marketing of consumer products containing synthetic human pheromones and other mood enhancing compounds in the United States and internationally. It provides a line of fragrance and toiletry products for men and women under the Natural Attraction trademark. The company also licenses its initial compounds and related technology, as well as sells its patented compounds to licensed customers to include these compounds as components in their products. In addition, it offers private label manufacturing services to licensed customers. Human Pheromone Sciences, Inc. distributes its products through distributors, as well as through the Web site, naturalattraction.com. The company was formerly known as EROX Corporation and changed its name to Human Pheromone Sciences, Inc. in May 1998. Human Pheromone Sciences, Inc. was founded in 1989 and is headquartered in San Jose, California.FOMO OTCMKTS:ETFM$0.0025 0.00 (0.00%) As of 07/3/2025FOMO Corp. focuses on incubation and acceleration business. The company invests in and advises emerging companies aligned with a growth mandate. It develops various direct investment and affiliations. The company was formerly known as 2050 Motors, Inc. FOMO Corp. was founded in 2012 and is based in Chicago, Illinois.Lee Pharmaceuticals OTCMKTS:LPHMLee Pharmaceuticals, Inc., through its subsidiary, RONN Motor Group, Inc., focuses on the design and development, manufacture, marketing, and sale of all-electric, hydrogen-fuel cell, and zero-emission new energy vehicles (NEVs) in the United States, China, and internationally. It intends to offer hydrogen fuel cell NEVs, including sports cars, sedans, SUVs, trucks, and buses. The company was founded in 2013 and is based in Scottsdale, Arizona. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
